Background Age-associated decline in central cholinergic activity makes older adults susceptible to the harmful effects of anticholinergic (AC) medications; however, there is an inadequate understanding of the association and possible effects of AC drugs on cognition. This crosssectional study examines the associations of AC medications on cognition among older adults with questionable cognitive impairment (QCI). Methods For this cross-sectional study, we used a multicenter database of community-dwelling older adults (N = 7351) aged 60? years with QCI, from September 2005 to March 2014, as the baseline data. The Anticholinergic Drug Scale was used to categorize AC drug load into no, low, or moderate/high groups. Individuals with a Clinical Dementia Rating-Sum of Boxes score between 0.5 and 2.5 were identified as having QCI, while cognitive performance was evaluated using the Neuropsychological Test Battery. The mean z-scores of neuropsychological tests were grouped into a global cognition score.
Introduction
Approximately 5.3 million people [1] in the US suffer from Alzheimer's disease (AD) and, with the increasing older population, the incidence of AD is expected to triple over the next 40 years [2] . Notably, 60-80 % of the overall dementia cases are identified as dementia of Alzheimer's type. AD is characterized by cortical cholinergic deficits, cognitive impairment, and dementia [3] . The cholinergic deficit was once considered the key pathophysiological dysfunction causing dementia, which led to the cholinergic hypothesis of AD [4] . Various studies have established that cholinergic neuronal loss, acetylcholine receptor dysfunctions, and signaling dysregulation are associated with decline in learning and memory in AD [5, 6] , and the severity of dementia is directly correlated with atrophy and degeneration of the brain cholinergic pathways [7, 8] . However, less is known about whether the exogenous use of anticholinergic (AC) medications is connected to agerelated cognitive impairment.
Previous studies have shown that older adults with exposure to AC medications were at increased risk of adverse drug events [9, 10] , especially those related to decline in cognitive [11] [12] [13] and physical abilities [14] . Although there has been considerable attention directed at monitoring and minimizing AC drug load to minimize cognitive impairment, these medications with moderate/ high AC properties, such as oxybutynin for urinary incontinence and carbamazepine for neuropathic pain, are frequently prescribed, and medications such as diphenhydramine (trade name: Benadryl) are readily available overthe-counter as general antihistamines [15] . Despite these clinical benefits, there are clear biological adverse effects on cognition [16] through unselective antagonism of muscarinic receptors in the brain [17] . Unfortunately, older adults are more susceptible to central antimuscarinic adverse effects [18] , making them more vulnerable to the adverse effects of AC drugs.
Current understanding of the effects of AC drugs on human cognition is derived largely from the studies that compare the effects of AC medication on individuals with mild cognitive impairment (MCI) or dementia with individuals with normal cognition [19] [20] [21] [22] . Previous observational studies have reported that moderate/high AC burden is associated with a greater risk of cognitive impairment and long-term cognitive decline in older adults [11] [12] [13] [23] [24] [25] . However, the pathophysiological process of AD and associated dementia begins years before the emergence of clinically detectable signs and symptoms [19] , and thus provides a window of opportunity to identify individuals with minimal cognitive impairment, and intervene and delay the process of cognitive decline in the very early stage of dementia. The Clinical Dementia RatingSum of Boxes (CDR-SOB) is a tool used to assess and classify levels of cognitive impairment in various categories. Its questionable cognitive impairment (QCI) category identifies individuals between normal cognition and MCI. On the path of dementia development, QCI is the first stage of cognitive impairment between normal cognition and full-blown dementia. It is the neuropsychological profile of a patient in the very early stage of cognitive impairment that does not manifest clinical signs or symptoms of cognitive decline but can be revealed on neuropsychological assessments. When QCI worsens, patients move from QCI into the MCI stage [26, 27] . Therefore, QCI provides the opportunity to identify a select number of people who might be vulnerable to the effects of AC medications and have elevated risk of clinical onset of MCI and dementia. Understanding the effects of AC medications in this vulnerable group will not only provide greater insight into the role of AC medications on cognition but also help in planning strategies to delay cognitive decline in this group. However, there is a major gap in understanding the role of AC exposure in older adults with QCI. Therefore, the objective of the current study was to assess the associations of AC medication exposure on cognitive performance among older adults with QCI. We hypothesize that older adults with QCI who have exposure to AC drugs are more likely to have poor cognitive scores compared with older adults who have no exposure to AC drugs.
Methods

Study Participants
This study is part of a larger, multicenter, longitudinal cohort database-the National Alzheimer's Coordinating Center (NACC)-that includes community-dwelling older adults with normal cognition, MCI, dementia, and AD [28] . The NACC contains a comprehensive database, the Uniform Data Set (UDS), from 34 collaborating AD centers (ADCs) [29] . The sample for this study consists of individuals from the NACC UDS data who participated in the study from September 2005 to March 2014 and who were selected from the hospital, patient, and physician referrals. Individuals aged 60 years and older were enrolled in the study (in 2005) , and their baseline AC exposure and cognitive functions were evaluated at the time of enrollment. QCI was determined using a reliable and valid instrument-the Washington University CDR-SOB scale [30] . The CDR-SOB score is a detailed quantitative rating scale with a wide range of values (0-18) identifying various stages of cognitive impairment differentiating between QCI and MCI. For our analysis, QCI was defined as a CDR-SOB score between 0.5 and 2.5 [31] .
Anticholinergic Exposure
To assess AC drug exposure, we used the valid and reliable Anticholinergic Drug Scale (ADS), an ordinal drug scale that rates medications according to increasing potency of their AC activity [32] . The ADS includes 413 medications covering approximately 88 and 89 % of regular and asneeded drugs, respectively. Either a clinician or trained research staff recorded each participant's prescription drugs, non-prescription medications, and vitamins/supplements using a standard medication inventory. The medication list included various medication groups, such as antivirals, antibiotics, antidepressants, antihistamines, antipsychotics, anti-anxiety medications, analgesics, cardiovascular drugs, muscle relaxants, H2 antagonists, corticosteroids, anticonvulsants, etc.
ADS scores are divided into four levels (0, 1, 2, and 3), according to AC drug activity [32] . ADS level 0 includes drugs with no known AC properties; ADS level 1 includes drugs in which AC activities can be assessed by receptor binding study; ADS level 2 includes drugs that show AC adverse events at excessive doses; and ADS level 3 includes drugs that have marked AC properties. The ADS also includes prescription medications, such as galantamine, rivastigmine, donepezil, and memantine, approved by the US FDA to treat individuals diagnosed with AD, as these medications do not have AC properties and are therefore included in ADS level 0. For the purpose of our study, we categorized the ADS drugs into three levels: level 1 indicates drugs with no known AC properties (e.g. cetirizine); level 2 indicates drugs with low potential AC activity (e.g. diazepam); and level 3 was created by combining ADS levels 2 (e.g. ranitidine) and 3 (e.g. oxybutynin), which represent medications that have moderate/ high AC adverse effects. The cognitive harm done by ADS level 2 and 3 drugs are deleterious enough to manifest clinically significant cognitive impairment, which can be identified on clinical assessment. Therefore, based on the clinical significance of medications in the ADS level 2 and 3 groups, in this study we decided to combine both categories into one single category (level 3).
The NACC assessed participants' medication use of prescription, non-prescription, and over-the-counter medications, as well as supplements, taken within 2 weeks prior to their baseline and follow-up visits. The NACC recorded drugs from various medication groups, such as antibiotics, antidepressants, antihistamines, antipsychotics, anti-anxiety medications, cardiovascular drugs, H2 antagonists, and anticonvulsants.
Cognitive Outcomes
We used the NACC's standardized Neuropsychological Test Battery (NTB), which can predict progression from QCI to dementia and can demonstrate age-related changes in cognitive domains, to assess cognitive functions in the early stage of cognitive impairment [33] . The NACC NTB assessed attention using Digit Span Forward and Digit Span Backward tests from the Wechsler Memory ScaleRevised (WMS-R). Decline in episodic memory, a hallmark of early AD, was evaluated using Logic Memory IA, and delayed recall was evaluated using Logic Memory IIA. Executive functions were assessed using the Trail Making Part A (TM-A) and B (TM-B) tests and the Digit Symbol Substitution Test (DSST). Language (verbal fluency and naming) was assessed using animal and vegetable list generation tests and a short version of the Boston Naming Test (BNT), respectively. Hayden et al. performed exploratory and confirmatory factor analysis of the NACC UDS NTB, and grouped 12 NTB measures into four cognitive domains [34] . We used this factor structure approach of Hayden et al. and grouped cognitive measures into the four cognitive domains-memory, attention, executive, and language. These domain-specific cognitive measures were our secondary outcome. The domain scores were calculated as the mean z-scores of relevant cognitive tests, and global cognition score, the primary outcome, was calculated as an average of the four domain scores (Online Resource 1). Since the lower TM-A and TM-B scores indicate better executive functions, we reversed the sign of the z-scores of TM-A and TM-B, and added to the z-score of DSST, to assess the executive functions in a common direction, i.e. higher scores indicate better cognitive functions.
The conceptual framework and the current literature guided the selection of independent variables. Previous studies have demonstrated an association between dementia and demographic factors, lifestyle behaviors, clinical conditions, and genetic biomarkers [23] [24] [25] . Demographic characteristics included age, sex, race, education, marital status, living situation, and family history. The lifestyle factors that affect cognition were smoking, alcohol consumption, and body mass index, and the clinical conditions included comorbidities such as cardiovascular disease, cerebrovascular disease, depression, neurological diseases, and diabetes. Cardiovascular disease consisted of cardiac arrest, atrial fibrillation, congestive heart failure, and patients with procedures such as angioplasty, cardiac bypass surgery, and pacemaker implant, while cerebrovascular disease included patients with stroke and transient ischemic attack. Neurological disease involved seizures, traumatic brain injury, and other neurological deficits. Diabetes, vitamin B12 deficiency, thyroid disease, and incontinence were identified by medical and prescription records, and by subject or co-participant report, while depression was identified using the Geriatric Depression Scale and self-report at the time of enrollment. We also controlled for the ApoE4 gene, a well-known genetic risk factor for AD and cognitive impairment [22] .
Statistical Analysis
We performed descriptive analysis to evaluate the distribution of means and proportions of baseline characteristics such as demographics, lifestyle factors, clinical conditions, and genetic predisposition stratified by levels of AC burden (no, low, and moderate/high AC use). We performed analysis of variance to evaluate differences in the means of continuous variables, and the Chi-squared test was used to evaluate differences in the distribution of categorical variables. Descriptive statistics allowed us to quantify and compare the distribution of different cognitive measures among AC drug levels.
In this cross-sectional analysis, the potential association between lower cognitive scores on global cognition and cognitive domains among individuals taking AC drugs was examined using general linear models (GLM). To evaluate the primary outcome, a GLM was fitted to estimate the independent association of AC drug exposures on global cognition score at baseline according to ADS levels. In addition, to assess the effects of AC drug use on specific cognitive domains, we built domainspecific models to evaluate the independent association between AC drug exposure and cognitive domains of memory, attention, executive functions, and language. We checked the linear model assumptions of independence, normality, and equal variance, and also checked independence by plotting each residual against neighboring values, i.e. residual lag plot. We illustrated the normal probability plot to observe against normal distribution values. Furthermore, we checked for the assumption of equal variance through residual plot examination. The statistical significance level was set at a = 0.05, and analysis was performed using SAS version 9.3 (SAS Institute, Inc., Cary, NC, USA).
Results
A total of 7315 participants met the inclusion criteria at baseline (2005). The mean age ± standard deviation (SD) of the sample was 74.8 ± 7.9 years (range 60-109), 81.6 % were White, and 51.8 % were females. Approximately 91 % had high-school or higher education, a percentage that appears to be high; however, there is similarity between the education levels of our cohort of older adults with QCI and other cohorts of preclinical AD [33, 35, 36] . Thus, our results can be generalized to this specific older population group. Approximately 63.5 % were married and 76.5 % were living independently, while approximately 15.7 and 4.1 % of participants were taking low and high levels of AC medication, respectively. Table 1 shows the population characteristics across the no, low, and moderate/high AC medication groups at baseline (2005). Compared with those who did not take AC medications, individuals who took low or moderate/high AC medications were slightly older (74.5 ± 7.8 vs. 76.6 ± 8.2 vs. 75.6 ± 7.8; p B 0.001), had higher BMI (27.1 ± 5.05 vs. 27.5 ± 5.5 vs. 27.4 ± 5.7; p = 0.02), were less likely to be married (65 vs. 60 vs. 57 %; p B 0.001), were more likely to live alone (27 vs. 31 vs. 33 %; p B 0.001), and were less likely to live independently (77 vs. 74 vs. 75 %; p = 0.01). The most commonly used medications with no AC properties were aspirin (48 %), multivitamins (38 %), and donepezil (27 %), and the most commonly used medications with low AC properties were furosemide (9 %), warfarin (8 %), and sertraline (7 %). Among the medications that had moderate/high AC properties, ranitidine (4 %), oxybutynin (4 %), and alprazolam (3 %) were the most commonly used drugs (Online Resource 2).
The mean scores (Table 2) (Table 3) , controlling for baseline demographics, lifestyle, comorbidity, and genetic factors, the global cognition score was estimated to be 0.064 greater for the low-AC medication group than the no-AC medication group (p = 0.006). The global cognition score among the moderate/high-AC medication group was also estimated to be 0.064 higher compared with the no-AC medication group, but was not statistically significant (p = 0.12). The fully adjusted model explained approximately 15 % of the variation in the model (r 2 = 0.15). Similarly, cognitive scores among the moderate/high-AC medication group in the attention domain, and the low-AC medication group in the language domain, were higher by 0.214 (p = 0.004) and 0.090 (p = 0.03), respectively, compared with those who did not take any AC medication.
Discussion
To our knowledge, this is the first population-based study to determine the association between AC medication use and cognitive functions in older adults with QCI based on their CDR-SOB score. The objective of this study was to assess the associations and possible effects of AC medication use on cognitive functions among older adults with QCI. We hypothesized that older adults with QCI who have exposure to AC drugs are more likely to have poor cognitive scores compared with older adults who have no exposure to AC drugs. Our study results showed that older adults with QCI who took AC medication had a higher cognitive score compared with those who did not take AC medication. These associations were statistically significant for those who took low AC medication, but were not significant for those who took moderate/high AC medication. Moreover, these associations were independent of demographic factors, clinical conditions, and APOE biomarkers that might influence cognition. Nonetheless, older adults with QCI who took moderate/high AC medication had a greater score in the attention domain, and those who took low AC medication had a greater score in the language Data are expressed as n (%) unless otherwise specified AC anticholinergic, APOE4 allele producing the e4 type of apolipoprotein E, SD standard deviation domain, compared with those who did not take AC medication. Furthermore, a higher global cognition score of 0.064 indicates that the overall cognitive functions among individuals who took low and moderate/high AC medication were greater than for those not taking AC medication, by a small but significant margin measured over 10 cognitive tests (Online Resource 1), with consistent results across the cognitive domains (Table 2 ). This clinically significant finding is notable as previous studies have shown an overall decrease in cognitive scores due to AC exposure. In pharmacoepidemiological research, prevalent user bias may modify the interpretation of an outcome. In this study, the medications were prescribed to patients for various clinical conditions not directly related to cognitive performance. Furthermore, it is possible that AC medications might influence the risk factors in the causal pathway that regulate cognitive performance. However, if AC medications had influenced covariates, this would have reduced cognitive performance, as shown in a previous study [37] . Moreover, in this study we found that AC use was associated with a higher cognitive score, which highlights that prevalent user bias could be ruled out in this study. In case of a potential prevalent user bias in observational studies, new-user designs can be implemented, such as excluding prevalent users from the study, selecting comparative cohorts of equal exposure and follow-up periods, performing analysis from the start of the medication therapy, and including all early events in the analysis. In our study, we found that the cognitive scores were significantly higher among individuals using AC medications compared with those who did not use AC medications. In contrast with others, we found that there was no dose-response association between increased AC medication use and decreased cognition in the QCI population [16, 38, 39] . These findings differ from the findings of previous population-based studies that used the list-based method to assess AC medication load among cognitively healthy older adults or demented populations [12, 13, 40, 41] . However, our findings are compatible with a previous study that found non-demented patients were significantly less susceptible to the adverse cognitive effects of AC medication than those with AD [42] , indicating that older adults with QCI, compared with MCI or pre-existing dementia, might be less susceptible to the adverse effects of AC medications. One recent longitudinal study showed that AC medication use did not deteriorate cognition over a period of 18 months [34] . Therefore, our study results point to a specific population that may possibly benefit from AC medication use; however, further studies are needed to replicate and clarify a causal relationship for our findings. In this study, we found that compared with men, women took more medication with moderate/high AC properties, which might be attributed to greater longevity and potential age-associated comorbidities among women [43] . Furthermore, the prevalence of incontinence is higher among women. One of the most commonly prescribed medications to treat incontinence is oxybutynin, which has a very high AC potency [44] . Similarly, a greater proportion of patients with Parkinson's disease took medications with moderate/high AC properties, such as bromocriptine. Therefore, it is important for clinicians to identify patients who might be at greater risk of AC adverse effects due to the AC medications.
One of the major reasons pertaining to our results is our new approach of choosing individuals who had belownormal cognitive scores on neuropsychological assessments, but did not manifest clinically significant cognitive deficiency, i.e. QCI. In the early stage of cognitive impairment, the preservation of cognitive functions can be attributed to the compensatory effect of non-cholinergic neurons, such as hyperinnervation of forebrain galaninergic fibers and proliferation of galaninergic receptors [45] . In addition, the acetylcholine-synthesizing enzyme, choline acetyltransferase, and number of cholinergic neurons, increases in early cognitive impairment, preserving the cognitive functions [46, 47] . Furthermore, interaction between cholinergic systems and other neuromodulators, such as norepinephrine, dopamine, serotonin, and caminobutyric acid (GABA), plays a vital role in modulating cognitive response in older adults [48] . Consequently, these compensatory mechanisms may preserve the cholinergic enzyme activities and cognitive functions in the early stages of cognitive impairment [47] .
Since our study sample was at a very early stage of cognitive impairment, participants may have preserved cognitive functions by initiation of compensatory mechanisms, and may have been less susceptible to the side effects of AC medication. Dumas and Newhouse found that scopolamine (a muscarinic acetylcholine receptor antagonist) and mecamylamine (a nicotinic acetylcholine receptor antagonist) improved frontal and hippocampal activations compared with placebo, providing evidence for cognitive compensation during the early phase of cognitive impairment [49] . In addition, Oberauer and Naveh-Benjamin et al. showed that comorbidity in older adults may alter cholinergic functioning and may decrease the ability of older adults to use the frontal brain-mediated compensatory control of cognitive functions that impairs memory [50, 51] . Hence, it is important to note that older adults with intact cholinergic functions will have greater compensatory benefit than those with advanced dementia. Our results show that individuals who took AC medications had higher global and domain-specific cognitive scores compared with those who did not take AC medications. In light of the current evidence, we theorize that our study population of older adults with QCI may have had intact cholinergic functions and may have benefited from some level of compensatory response; the AC medications would have provided additional cognitive benefit by alleviating comorbidity burden on cognition.
We speculate that the QCI population responds to the therapeutic actions of AC medications, and that the therapeutic effects of AC medications offset any potential iatrogenic AC overload that may manifest cognitive side effects. Supporting our premise, previous studies show that clozapine, a highly potent AC drug, improved attention, reaction time, executive functions, working memory, and verbal fluency among schizophrenic individuals [52] . Recent community-based cohort studies demonstrated an overall decrease in incident dementia among cognitively normal older adults who were treated with antihypertensive drugs [53] . Other studies have also provided evidence that antihypertensive medications, such as brain-penetrating angiotensin-converting enzyme inhibitors and calcium channel blockers, not only decrease the risk of dementia among individuals with hypertension but also slow the progression of dementia [54] [55] [56] . This evidence demonstrates that it is likely that the better cognitive scores among individuals with QCI may partly reflect the treatment effect of AC medications, consequently reducing the cognitive burden of comorbidities.
It is important to note that medications such as captopril, nifedipine, diltiazem, etc., which have been shown to reduce the overall burden of dementia, also have low AC properties. This dual action of medications to alleviate the comorbidity effects of dementia while contributing to AC burden on the brain, shows that it is very difficult to separate the AC effects of medications from their potential benefits. Hence, the overall impact of AC medications can be measured by their cumulative effects on cognition in the presence of other predictors such as comorbidity. Due to the complexity of the cognitive processes, and their association between pathobiological and clinical manifestations, there is limited understanding regarding the mechanism of specific vulnerability to AC medications [57] . It might be possible that neuromodulators might interact with cholinergic systems and mask the AC medication effects, especially in the early stages of cognitive impairment. Therefore, in addition to considering the independent effects of the cholinergic system, it is important to include the interactions between neuromodulators and the cholinergic system. The NACC dataset lacked information regarding neuromodulatory systems, which limited the possibility of assessing the effects of neuromodulators on the cholinergic system and the cognitive profile of older adults.
The strengths of this study lie in its use of the NACC data from the large population-based prospective study of older adults across the US. The NACC includes one of the largest number of participants in the standardized longitudinal data, which allows us to parcel out a QCI population to study. Additionally, we were able to use a reliable and validated method (the ADS) to assess AC load. Furthermore, the NACC data allowed us to take into account various competing causes of cognitive dysfunction in older adults by adjusting for socioeconomic, demographic, health, lifestyle, and genetic factors, thus limiting any potential confounding.
Our study has some limitations. Participants' medication use was collected based on self-reports. In addition, medication history in the NACC dataset is limited to only 2 weeks before the visit date. Another limitation of the NACC medication records is the absence of the frequency and doses of medication. Even if this information was available, the ADS does not incorporate the frequency or doses of medications to assess AC drug burden. Moreover, AC drug effect is not only related to the dose of each individual medication but also to the accumulated burden of AC medications. Additionally, the NACC population was selected from hospital, patient, and physician referrals, which might not be a true representation of communitydwelling older adults in the US, and the results may not generalize to the overall population of older adults. Finally, the cross-sectional nature of this study prevented us from evaluating causality, and a longitudinal study is thus necessary to better assess the long-term effects and trends of AC medications on cognitive performance. Despite these limitations, the NACC dataset is an appropriate resource to assess associations between AC medication burden and cognitive function.
Conclusions
These results indicate that older adults with QCI taking medications with AC properties had higher cognitive scores than those not taking AC medications. We cannot definitely rule out the possibility of cholinergic modulators and other unknown factors acting to preserve cognitive reserve in QCI. Nevertheless, our results suggest that the therapeutic effects of AC medications might be beneficial to cognition among the QCI population; however, the relationship between AC medication use and cognitive functioning in the elderly is complex. Given the lack of significant adverse effects of AC use in this large sample, it is questionable that AC drug use causes cognitive dysfunction among people with subtle memory and cognitive difficulties. Thus, more research is needed to understand and assess the impact of AC medications on QCI populations. In addition, future research should also consider cognitive modulators in order to identify the clinically meaningful effects of AC exposure groups.
